131 related articles for article (PubMed ID: 23986058)
1. [A case of advanced esophagogastric junction cancer responding to pre-operative combination chemotherapy of docetaxel, cisplatin, S-1, and trastuzumab].
Haruki S; Takiguchi N; Arita K; Usui S; Ito K; Matsumoto A; Hiranuma S; Bhunachet E
Gan To Kagaku Ryoho; 2013 Aug; 40(8):1089-92. PubMed ID: 23986058
[TBL] [Abstract][Full Text] [Related]
2. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
3. [A case of HER2-positive esophagogastric junction cancer treated by using a neoadjuvant chemotherapy regimen consisting of trastuzumab].
Kanaya N; Arata T; Tanakaya K; Yamasaki R; Aoki H; Takeuchi H
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2285-6. PubMed ID: 25731497
[TBL] [Abstract][Full Text] [Related]
4. [A Case of HER2-Positive Siewert Type I Adenocarcinoma of the Esophagogastric Junction Treated via Neoadjuvant Chemotherapy Followed by Radical Resection].
Nakajima T; Sato T; Kano K; Maezawa Y; Segami K; Fujikawa H; Ikeda K; Yamada T; Ogata T; Cho H; Yoshikawa T
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1240-1242. PubMed ID: 27760947
[TBL] [Abstract][Full Text] [Related]
5. [A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Murakami K; Tamura S; Takeno A; Ishida T; Kuwahara R; Akiyama Y; Sakamoto T; Inatome J; Naito A; Katsura Y; Ohmura Y; Kagawa Y; Egawa C; Takeda Y; Kato T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2010-2012. PubMed ID: 28133205
[TBL] [Abstract][Full Text] [Related]
6. [A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil].
Matsutani T; Uchida E; Maruyama H; Suzuki S; Yokoyama T; Matsushita A; Hirakata A; Kawamoto M; Arai H; Umakoshi M; Wakabayashi H; Sasajima K
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1949-52. PubMed ID: 20948262
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
8. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
9. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
10. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Advanced Esophageal Cancer Successfully Treated with DCF Chemotherapy Followed by Conversion Surgery].
Okada K; Takeoka T; Miki H; Kobayashi K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1623-1625. PubMed ID: 29394722
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Recurrent Esophagogastric Junction Cancer Responding to Trastuzumab].
Kobayashi Y; Hirao M; Yamamoto K; Nishikawa K; Maeda S; Uemura M; Miyake M; Hama N; Miyamoto A; Miyazaki M; Ikeda M; Nakamori S; Sekimoto M; Mori K; Mano M
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2181-2183. PubMed ID: 28133262
[TBL] [Abstract][Full Text] [Related]
13. [A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab].
Toshima H; Hisamatsu A; Shimada K; Saito M; Suzuki M; Matsukawa M; Inoue H
Gan To Kagaku Ryoho; 2016 Jun; 43(6):761-4. PubMed ID: 27306816
[TBL] [Abstract][Full Text] [Related]
14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
16. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
17. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
18. [Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU].
Nishino T; Yamamoto Y; Ikeda M; Morimoto M; Furukawa T; Goto M; Furukita Y; Takechi H; Seike J; Tangoku A; Fujiwara H
Gan To Kagaku Ryoho; 2013 May; 40(5):643-6. PubMed ID: 23863591
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Kuga Y; Kitamura S; Mouri T; Miwata T; Sakimoto H; Nishida T
Gan To Kagaku Ryoho; 2017 Mar; 44(3):247-249. PubMed ID: 28292996
[TBL] [Abstract][Full Text] [Related]
20. [A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Jeongho M; Hatanaka N; Odagiri K; Kurokawa T; Honmyo N; Yamashita S; Inoue M; Irei T; Shimizu Y; Tanemura M; Tominaga H
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2290-2. PubMed ID: 25731499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
